NCT03106610View on ClinicalTrials.gov

Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

July 7, 2017

Primary Completion Date

May 16, 2018

Study Completion Date

May 16, 2018

Conditions
Bladder Cancer
Interventions
DRUG

Nivolumab

3 mg/kg of body weight by vein over about 60 minutes on Day 1 of Cycles 1-3.

BEHAVIORAL

Questionnaires

2 quality-of-life questionnaires completed on Day 1 of Cycles 1-3, at the visit before surgery, and 4 weeks after surgery.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER